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Background: Asymptomatic low-density gametocyte carriers represent the majority of malaria-infected individ-
uals. However, the impact of recommended treatment with single low dose of primaquine and an artemisinin-
based combination therapy to reduce transmission in this group is unknown.
Methods: This was a four-arm, open label, randomized controlled trial comparing the effect of
dihydroartemisinin-piperaquine (DHAP) alone or combined with single dose of primaquine (PQ) at 0.20
mg/kg, 0.40 mg/kg, or 0.75 mg/kg on Plasmodium falciparum gametocytaemia, infectiousness to mosquitoes
and hemoglobin change in asymptomatic, malaria-infected, glucose-6-phosphate dehydrogenase (G6PD) nor-
mal individuals. Randomization was done using a computer-generated sequence of uneven block sizes with
codes concealed in sequentially numbered opaque envelopes. The primary endpoint was the prevalence of P.
falciparum gametocytemia at day 7 of follow-up determined by quantitative nucleic acid sequence based assay
and analysis was by intention to treat. The trial has been concluded (registration number: NCT01838902;
https://clinicaltrials.gov/ct2/show/NCT01838902).
Results:A total of 694 asymptomatic, malaria-infected individuals were enrolled. Gametocyte prevalence at day 7
was 37.0% (54/146; 95% CI 29.2–45.4), 19.0% (27/142; 95% CI 12.9–26.4), 17.2% (25/145; 95% CI 11.0–23.5) and
10.6% (15/141; 95% CI 6.1–16.9) in the DHAP alone, 0.20mg/kg, 0.40mg/kg, and 0.75mg/kg PQ arms, respective-
ly. The main adverse events reported include headache (130/471, 27.6%), cough (73/471, 15.5%), history of fever
(61/471, 13.0%) and abdominal pain (57/471, 12.1%). There were ﬁve serious adverse events however, nonewas
related to the interventions.
Interpretation: A single course of PQ signiﬁcantly reduces gametocyte carriage inmalaria-infected asymptomatic,
G6PD-normal individuals without increasing the risk of clinical anemia. The limited number of successful mos-
quito infections suggests that post-treatment transmission potential in this asymptomatic population is low.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Asymptomatic, low-density infections constitute over 60% of the
human reservoir of malaria parasite (Laishram et al., 2012) and this
combined with long periods of carriage without progression to clinical
disease (Bereczky et al., 2004), even in low transmission settings, sug-
gests that asymptomatically infected individuals may contribute
substantially to malaria transmission (Alves et al., 2005; Mwesigwa
et al., 2015). In contrast, clinical malaria cases have been associated
with higher parasite densities. However, the relation between pre-
treatment asexual parasite density and gametocyte prevalence after
treatment has not been consistent. Antimalarial treatment clears the
asexual parasite load which in turn reduces gametocyte burden but
clearance of mature gametocytes present prior to treatment is incom-
plete and varies by treatment (WWARN Gametocyte Study Group,
2016). Therefore, for interrupting malaria transmission and eventual
elimination, efﬁcient surveillance and treatment of all persons infected
with both asexual stages and gametocytes (Slater et al., 2015) is
important.
Primaquine (PQ), an 8-aminoquinoline, is recommended in combi-
nation with an artemisinin-based combination therapy (ACT) in low
Plasmodium falciparum transmission settings to further reduce trans-
mission (World Health Organization, 2010). These drugs act compli-
mentarily: ACTs rapidly clear the P. falciparum asexual parasite
biomass as well as early gametocyte stages (Chotivanich et al., 2006),
considerably reducing post-treatment gametocyte carriage (WWARN
Gametocyte Study Group, 2016) while PQ clears mature gametocytes
(White, 2008). However, implementation has been slow because PQ
causes a dose-dependent hemolysis, particularly in individuals with
some deﬁciency of the red blood cell enzyme, glucose 6-phosphate de-
hydrogenase (G6PD) (Eziefula et al., 2014b). The mean prevalence of
G6PD deﬁciency variant in sub-Saharan Africa is 7.5% (Nkhoma et al.,
2009) but varies signiﬁcantly by and within country (Howes et al.,
2012). Lower PQdosesmay reduce the risk of hemolytic events. The rec-
ommended dose was recently reduced from 0·75 mg base/kg to
0·25 mg base/kg to minimize this risk of hemolysis (Global Malaria
Programme, 2015) while presumably retaining efﬁcacy (Ashley et al.,
2014; White et al., 2012). PQ's mode of action is unclear but may act
by sterilizing gametocytes and thus preventing fertilization in the mos-
quito; this effect precedes clearance of gametocytes from circulation
(White, 2013). The presence of circulating gametocytes is thus a poor
predictor of transmissibility (Karunajeewa andMueller, 2016). The efﬁ-
cacy of PQ has been measured by gametocyte clearance and infectious-
ness to mosquitoes. However, infectiousness studies are not well
standardized and this affects their suitability for evaluating efﬁcacy of
transmission-blocking interventions (Bousema et al., 2012).
Early trials on the 0.75 mg/kg dose reported variable reductions in
gametocyte carriage (El-Sayed et al., 2007; Shekalaghe et al., 2011;
von Seidlein et al., 2003) and a dose-ranging trial in clinically ill patients
showed efﬁcacy at doses as low as 0.40 mg/kg (Eziefula et al., 2014a);
however, non-inferiority of the 0·1 mg/kg dose was inconclusive
(Eziefula et al., 2014a). More recent studies in high transmission areas
and high-density gametocyte carriage conﬁrm that PQ reduces gameto-
cyte carriage and infectiousness to mosquitoes over a range of doses
that includes the currently recommended 0.25 mg/kg (Dicko et al.,
2016; Goncalves et al., 2016). There are indications that the added
value of PQ in reducing post-treatment infectivity may differ between
symptomatic and asymptomatic infections (El-Sayed et al., 2007;
Shekalaghe et al., 2007) and the dynamics of asymptomatic low-
density parasite carriage may be markedly different (WWARN
Gametocyte StudyGroup, 2016), perhaps due to longer periods of infec-
tion in asymptomatic infections and hence more circulating mature ga-
metocytes (Price et al., 1999; Stepniewska et al., 2008). Therefore, there
is the need for evidence on the efﬁcacy and safety of these PQ doses in
asymptomatic individuals with low-density malaria infections and
their impact on infectiousness to mosquitoes.
This study compared the gametocytocidal efﬁcacy of three different
single doses of PQ combined with dihydroartemisinin-piperaquine
(DHAP) on gametocyte carriage in asymptomatic, malaria-infected,
G6PD-normal individuals in The Gambia. Infectivity to Anopheles
coluzziimosquitoes was measured in a subset of enrolled participants.
2. Method
2.1. Study Design and Participants
This was a 4-arm, parallel open-label randomized controlled trial
conducted in the Central and Upper River Regions of The Gambia. The
trial protocol with details of the design has been published previously
(Okebe et al., 2015). Asymptomatic individuals with P. falciparum
mono-infection and a parasite density N20 parasites/μl were identiﬁed
by systematic community-based screening after an informed consent.
Additional eligibility criteria included: age N1 year, axillary temperature
b37.5 °C andnohistory of fever in the 24 h before the visit, normal G6PD
status determinedbyﬂuorescent spot test (N. Dimopoulos SA) and a he-
moglobin value ≥8 g/dl (HemoCue, Ängelholm, Sweden). Individuals
who reported sickle cell disease, antimalarial use within two weeks
prior to screening, current pregnancy or history of allergy to the study
drugs were excluded.
2.2. Randomization and Allocation Concealment
All participants received DHAP (Sigma-Tau IFR S.p.A, Italy) and in
addition, three of the four arms were randomized to receive a single
dose of PQ at 0.75 mg, 0.40 mg or 0.20 mg base/kg body weight using
a computer-generated sequence of uneven block sizes. In the ﬁrst
phase of the study (participants 1–347) PQwas procured from the Gov-
ernment Pharmaceutical Organization in Thailand; during the second
phase of the study (participants 348–694) PQ was procured from
Sanoﬁ®, (Forest Park, GA, USA). The source was changed to harmonize
the intervention with other on-going trials with PQ (Eziefula et al.,
2012). The randomization codes for the trial armswere concealed in se-
quentially numbered opaque envelopes and opened by the study clini-
cian to reveal the allocation arm and, based on body weight, calculate
the dose for both DHAP and PQ. A separate randomization sequence
was used to select a third of those enrolled in the trial for membrane
feeding experiments.
2.3. Treatment and Procedures
DHAPwas given once daily for 3 days on an empty stomachwhile PQ
was given on the last day of ACT treatment at least one hour after the
last dose of DHAP with a light snack. For small children, a tablet of PQ
(15 mg base) was crushed and reconstituted in 15 ml of water to pro-
duce a 1 mg/ml suspension and the required dose was drawn, to the
nearest 0.1 ml, mixed with orange juice and administered. A study
nurse directly supervised all treatments and the participant was ob-
served for 30 min for any reaction; if the drug was vomited within
this period, it was repeated.
The choice of administration of PQ on day 2 was based on available
evidence (Eziefula et al., 2012). ACTs have been shown to sharply re-
duce gametocyte density with the most pronounced effect within the
ﬁrst three days of administration, after which there is a more gradual
decay of persisting gametocytes (Bousema et al., 2010). Therefore, giv-
ing PQ on day 2 provides a clearer indication of its gametocyte-
clearing effect. Also, administering PQ on day 2 could limit the impact
of both the clinical disease and treatment on hemoglobin levels
(Eziefula et al., 2014a).
Participantswere reviewed on days 1, 2, 3, 7, 10, 14, and thenweekly
till day 42 with clinical examinations and blood samples collected for
hemoglobin check and for quantifying gametocytes marker Pfs25
mRNA by quantitative nucleic acid sequence based ampliﬁcation (QT-
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NASBA) according to published protocols (Schneider et al., 2004). For di-
rect membrane feeding experiments, 3 ml of venous blood was collected
on day 7 and fed to 100 locally reared 4–5 day old female Anopheles
coluzzii mosquitoes through an artiﬁcial membrane (Ouédraogo et al.,
2013). Unfed and partially fed mosquitoes were removed after feeding
while fully fed mosquitoes were kept at 28 (±1) °C and 75% humidity
for seven days. Surviving mosquitoes were dissected in 1% mercuro-
chrome (Valdafrique Laboratoires Canonne, Ruﬁsque) and their midguts
examined for oocysts under the microscope.
Giemsa stained blood slides were examined under a microscope for
asexual stage parasites andwhen seen, were counted against 500white
blood cells (assuming white blood cells count of 8000/μl). A slide was
declared negative if no parasites were seen after examining 100 high-
power ﬁelds. Microscopy results were primarily used for the clinical
care of participants.
3. Data Management
Clinical data were single-entered onto the database (OpenClinica
LLC, Waltham, MA, USA) and veriﬁed from the source documents
while DMFA resultswere double entered on aMicrosoft Access database
(Microsoft Corp., Richmond, WA, USA). The QT-NASBA results were au-
tomatically extracted as Microsoft Excel document (Microsoft Corp.,
Richmond, WA, USA) and linked to the rest of the dataset.
3.1. Outcomes
The primary study endpoint was the prevalence of P. falciparum
gametocytemia at day 7 of follow-up determined by QT-NASBA. Sec-
ondary outcomes were gametocyte prevalence during follow up,
change in hemoglobin values during follow-up, infectiousness to mos-
quitoes on day 7 deﬁned by the number of individuals with feeds
resulting in ≥1 infected mosquito, the number of adverse and serious
adverse events. The day 7 primary endpoint takes into account PQ's rel-
atively short half-life and the period of maximum effect demonstrated
in previous studies (Eziefula et al., 2014a, Shekalaghe et al., 2007), and
it is in linewith the standardized endpoints proposedby the Primaquine
in Africa Discussion Group (Eziefula et al., 2012).
3.2. Sample Size Calculations
The study set out to test two hypotheses: i) PQ, at any dose, added to
a full course of DHAP, results in lower gametocyte carriage compared to
DHAP alone and ii) both the 0.40mg and 0.20mg base/kg PQ doses have
similar gametocytocidal efﬁcacies compared to the 0.75mgbase/kg.We
assumed gametocyte prevalence on day 7 of 25% for the ACT alone arm
in low transmission settings (Slater et al., 2015) and a 50% reduction
with PQ added, at any dose. A sample size of 220/arm had 90% power
and 5% signiﬁcance to detect this difference in prevalence, allowing for
10% non-compliance or loss to follow-up. For the second hypothesis of
non-inferiority of lower PQ doses compared to 0.75 mg base/kg, 300
participants/armwould have 90% power to detect that a conﬁdence in-
terval around the prevalence in the lower dose PQ arm was 8% less in
the 0.2 or 0.4 mg/kg PQ arms, assuming the prevalence of 13% at day 7
in the 0.75 mg base/kg arm.
4. Statistical Analysis
Descriptive statistics are presented by treatment arm at baseline and
gametocyte carriage compared using one way Analysis of Variance
(ANOVA) on log-transformed gametocyte densities at analyzed visits.
We determined the odds of gametocytemia on days 7, 10 and 14 in a
multivariable logistic regression model using a generalized estimating
equation with exchangeable correlation structure to control for poten-
tial confounding/effect modiﬁcation due to age, gender, baseline hemo-
globin level and asexual parasite count. We ﬁtted a Cox proportional
hazard model to determine the effect of PQ dose on gametocyte clear-
ance compared to the control adjusted for baseline asexual parasite
density and hemoglobin in those with gametocytemia on enrolment.
For this speciﬁc analysis only, baseline gametocytemia was deﬁned as
all QT-NASBA positive samples on either day 0 or day 3 (one day post-
PQ dose) to adjust for ﬂuctuation in gametocyte densities around the
threshold of detection of the QT-NASBA and hence gametocytemia as
changes during this period is most likely be due to the effect of the
ACT. A KaplanMeier estimator survival plot was used to show probabil-
ities of gametocyte carriage over time in the study arms. The change in
hemoglobin levels from baseline was calculated as the difference be-
tween the reference visit and baseline. All analyses were restricted to
gametocyte results between day 0 and 14 to minimize bias from possi-
ble new asexual infections that lead to de novo gametocyte production,
as DHAP concentrations beyond this time may no longer prevent the
emergence of new infections (Bousema et al., 2010). Analyses were
done using Stata 13.1 (Stata Corp, College Station, TX, USA) and based
on an intention-to-treat principle.
5. Ethics, Approvals and Trial Management
An independent Trial Steering Committee and a Data Safety and
Management Board reviewed the trial conduct. The trial was approved
by The Gambia Government/MRC Joint Ethics Committee (SCC 1321,
13 March 2013) and the London School of Hygiene and Tropical Medi-
cine Research Ethics Committee (ref 6412). A signed informed consent
was obtained from all participants; consent for children was provided
by the caregiver and an assent obtained from children between 12
and 17 years. The trial was conducted in conformity with the principles
of good clinical practice and the Helsinki Declaration.
6. Changes to the Trial Protocol after Initiation of the Study
The site in the Central River Region was relocated to Diabugu in the
Upper River Region due to low recruitment. However, due to distance of
this new site to the insectary, feeding experiments were limited to one
site and the randomization sequence adjusted while maintaining group
allocation.
At the end of the second recruitment season, the Trial Steering Com-
mittee reviewed the progress of the trial against the planned sample
size and the funding period. Although the number of individuals recruit-
ed was lower than the target sample size, the trial was sufﬁciently
powered to test the ﬁrst trial hypothesis. However, a much larger sam-
ple, beyond the initial projection, was required to prove non-inferiority
between PQ arms. Therefore, it was decided to close the trial.
7. Results
The trial was conducted over two transmission seasons: August
2013–February 2014 and August 2014–February 2015. The systematic
community-based screening identiﬁed 1011 persons with parasite den-
sity N20 parasites/μl of which 694 (68.6%) were enrolled. There were
306 (44·1%) males and the median (IQR) age and weight were 10 (7–
14) years and 28.2 (20.3–38.7) kg, respectively. Forty-seven (6 · 8%)
participantswithdrew from the study after enrolment; 27 of thesewith-
drew before day 7, and 24 (3 · 5%) were lost to follow up (Fig. 1). The
baseline gametocyte prevalence was 12 · 5% (85/680) by microscopy
and 52 · 3% (313/599) by QT-NASBA, with no difference between treat-
ment arms (Table 1). A total of 170 participants participated in mem-
brane feeding assays.
7.1. Primary Endpoint: Gametocyte Carriage on Day 7 After Treatment
The drop in gametocyte prevalence between day 0 and day 7 was
signiﬁcantly lower in all PQ arms compared to the DHAP alone arm,
with a mean difference (MD) of 34.3% (95% CI 24.1–44.7), 37.4% (95%
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CI 27.3–47.4) and 42.8% (95% CI 33.2–52.3) in the 0.20mg, 0.40 mg and
0.75 mg PQ arms, respectively (Fig. 2). A chi squared test showed a sig-
niﬁcant trend in gametocyte reduction on day 7 between study arms
(p b 0.001). Participants who received PQ arms had lower odds of
gametocytemia at day 7 compared to the DHAP arm: 0.20 mg (OR
0·38; 95% CI 0.22–0.66; p b 0.001), 0.40 mg (OR 0.33; 95% CI 0.19–
0.58; p b 0.001), and 0.75 mg (OR 0.20; 95% CI 0.11–0.38; p b 0.001),
after adjustment for baseline gametocyte density (Fig. 3).
7.2. Secondary Endpoint: Gametocyte Carriage During Follow Up
Gametocyte prevalence on day 3, one-day post PQ administration,
was not signiﬁcantly different compared to baseline in the control
(MD 9.6%; 95% CI–1.5 to 20.7; p = 0.092), 0.20 mg PQ (MD 10.2%; 95%
CI–1.1 to 21.6; p = 0.079), 0.40 mg PQ (MD 9.0%; 95% CI–2.2 to 20.3;
p = 0.119) and 0.75 mg PQ (MD 10.8%; 95% CI–0.6 to 22.2; p =
0.067) arms.
By day 14, prevalence was signiﬁcantly lower from baseline in the
0.20 mg (MD 42.4%; 95% CI 32.8–52.1; p b 0.001), 0.40 mg (MD 44.6%;
95% CI 35.3–54.0; p b 0.001) and the 0.75 mg PQ arms (MD 47.6%;
95% CI 38.4–56.6; p b 0.001) than in the control (MD 14.6%; 95% CI
3.5–25.7; p= 0.011). The odds of gametocytemia remained signiﬁcant-
ly lower in the 0.20 mg (OR 0.24; 95% CI 0.13–0.46; p b 0.001), 0.40 mg
(OR 0.20; 95% CI 0.10–0.40; p b 0.001) and the 0.75mg/kg (OR 0.12; 95%
CI 0.06–0.27; p b 0.001) PQ arms after adjusting for baseline gametocyte
density. Although the odds of gametocytemiawas lowest in the 0.75mg
arm, there was no signiﬁcant difference between the PQ arms (Fig. 3).
Gametocyte clearance was associated with PQ dose, being fastest in
the 0.75 mg PQ arm (hazard ratio (HR) 1.81; 95% CI 1.25–2.62; p =
0.002) followed by the 0.40 mg PQ (HR 1.53; 95% CI 1.06–2.20; p =
0.023) and the 0.20 mg PQ arm (HR 1.49; 95% CI 1·03–2·16; p =
Fig. 1. Flow diagram of the study. DHAP: dihydroartemisinin-piperaquine, PQ: primaquine, QT-NASBA: quantitative nucleic acid sequence-based assay.
Table 1
Characteristics of participants at enrolment.
DHAP only (N = 175) DHAP + 0.20 mgPQ (N = 172) DHAP + 0.4 mgPQ (N = 175) DHAP + 0.75mgPQ (N = 172)
Age in years 11 (8–14) 10 (7–14) 10 (7–15) 10 (7–14)
Male (%) 88 (50.3) 71 (41.3) 76 (43.4) 71 (41.3)
Axillary temperature (°C) 36.4 (0.4) 36.4 (0.4) 36.5 (0.4) 36.4 (0.4)
Hemoglobin (g/dl) 11.6 (1.9) 11.6 (1.7) 11.4 (1.4) 11.6 (1.6)
Asexual parasite density (/μl) 193 (48–688) 221 (48–648) 215 (48–672) 294 (48–1073)
Gametocyte prevalence by microscopy 7.1 (12/170) 13.5 (23/170) 15.8 (27/171) 13.6 (23/169)
Gametocyte prevalence by QT-NASBA 47.7 (73/153) 53.4 (79/148) 54.6 (83/152) 53.4 (78/146)
Gametocyte density by QT-NASBA (/μl) 11.7 (1.4–106.7) 12.9 (1.2–127.8) 11.3 (1.4–81.9) 10.7 (1.4–84.2)
Note: means and standard deviation are presented for temperature and hemoglobin; age is presented as median and interquartile range, geometric means and interquartile ranges are
presented for asexual parasite and gametocyte densities. QT-NASBA: quantitative real-time nucleic acid sequence-based analysis.
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0·033) after adjusting for asexual parasite density andhemoglobin level
(Fig. 4).
7.3. Secondary Endpoint: Infectivity to Mosquitoes in Membrane Feeding
Assays
The prevalence of gametocytemia at day 7, by microscopy and QT-
NASBA was 2 · 5% (4/161) and 28 · 0% (45/161), respectively
(Table 2). Two participants; in the control and the 0·20 mg/kg PQ
arms each infected ≥1 mosquito. In the control arm, one mosquito
was infected (1 · 3%, 1/80) with two oocysts while in the 0·20 mg/kg
PQ arm, 29 · 2% (19/65) of fed mosquitoes were infected, with oocyst
densities ranging between 1 and 3 per infected mosquito (27 in total).
Both individuals had gametocytes detected by QT-NASBA on day 7;
the participant in the control arm also had gametocytes detected by
microscopy.
7.4. Secondary Endpoint: Safety, Change in Hemoglobin Concentrations
The mean (SD) hemoglobin at baseline was 11 · 5 (1 · 6) g/dl and
did not vary signiﬁcantly between treatment arms (Table 1). Fifty-
three percent (337/637) of study subjects experienced a drop in hemo-
globin at day 7. However, 97.3% (328/337) of these were ≤25% of the
baseline value. The mean change in hemoglobin was largest on day 3;
however, most participants had returned to baseline values by day 10.
Overall, themean (95% CI) change in hemoglobin throughout the follow
upwas 0.12 g/dl (−0.01 to 0.25), 0.26 g/dl (0.14–0.38), 0.41 g/dl (0.29–
0.53) and 0.19 g/dl (0.05–0.33) in the control, 0.20 mg, 0.40 mg and
0.75mgPQ arms, respectively. The lowest hemoglobin value document-
ed in the trial was 4.7 g/dl recorded on day 3 in a 7-year old boy in the
0.75 mg PQ arm (starting value 8.3 g/dl) while the maximal fall in
hemoglobin value during follow-up was 7.5 g/dl on day 7 (starting
value 14.3 g/dl) in a female in the control arm. These participants did
not show clinical signs butwere treatedwith hematinics as per protocol
and recovered to baseline levels during follow up. Overall, no clinical
symptoms were observed with the changes in hemoglobin.
7.5. Secondary Endpoint: Adverse Events
There were 452 adverse events from 471 participants observed dur-
ing followup,with nodifference between treatment arms (Table 3). The
main complaints were headache (130/471, 27.6%), cough (73/471,
15.5%), history of fever (61/471, 13.0%) and abdominal pain (57/471,
12.1%). One participant had to be re-dosed after vomitingDHAP. Five se-
rious adverse events occurred during the trial and none was related to
the intervention. They include clinically diagnosed pneumonia (two
cases), meningitis (no organisms seen on bacterial culture), road acci-
dent and an iatrogenic abscess after receiving intramuscular quinine
by a third party. All events resolved completely.
8. Discussion
The vast majority of malaria infections in low endemic settings are of
low density (Imwong et al., 2016) but can contribute considerably to on-
ward malaria transmission (Slater et al., 2015). However, the impact of
current ACT and ACT-PQ on preventing onward malaria transmission
from these low-density infections has never been established. Our
study is the ﬁrst to determine the effect of single low dose PQ on
gametocytemia and infectivity tomosquitoes after treatmentwith a cur-
rently available ACT in asymptomatic, low-density infections. PQ is con-
sidered a potent gametocytocide to support community campaigns with
ACT. Althoughhigh community coveragewith efﬁcacious antimalarials is
arguably the most important factor in determining the success of com-
munity treatment campaigns (Johnston et al., 2014; Okell et al., 2011),
the drug itself is important (Okell et al., 2011) because antimalarials dif-
fer in their prophylactic and gametocytocidal effects (Stasinopoulos and
Rigby, 2007). The justiﬁcation for including PQ in community treatment
campaigns is that it shortens the infectious period after ACT (Dicko et al.,
2016) and may thus reduce community-wide malaria transmission po-
tential shortly after treatment. Previous studies with sulfadoxine-
pyrimethamine alone or with PQ at 0.75 mg/kg concluded that PQ con-
siderably reduced the duration of gametocyte carriage in symptomatic
patients (Shekalaghe et al., 2007); however, this was not the case in
asymptomatic, low-density infections (El-Sayed et al., 2007). Our study
demonstrates a statistically signiﬁcant reduction in the prevalence of
gametocytemia and shorter gametocyte carriage time following all PQ
doses compared to DHAP alone. This is consistent with the growing
Fig. 2. Gametocyte prevalence in each trial arms for each analyzed day of follow up. Error
bars indicates the upper limit of the 95% conﬁdence interval around the prevalence.
Fig. 3. Odds ratio of gametocyte prevalence on each of the days of follow-up compared
with the control arm adjusted for baseline gametocyte density. Bars indicate the upper
and lower limits of the 95% conﬁdence.
Fig. 4. Kaplan Meier plot for gametocyte clearance in individuals who were gametocyte
positive at enrolment.
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body of evidence showing that PQ is efﬁcacious for reducing gametocyte
carriage (Eziefula et al., 2014a; Dicko et al., 2016; Smithuis et al., 2010;
Goncalves et al., 2016; Shekalaghe et al., 2007). It is currently impossible
to predict infectivity to mosquitoes frommolecular gametocyte markers
only (White et al., 2014) andmosquito-feeding experiments remain im-
portant to draw conclusions on infectivity. Acknowledging these limita-
tions of gametocytemia as outcome measure, we aimed to support our
ﬁndings withmosquito feeding assays. We observed very low infectivity
inmembrane feeding experiments conducted at day 7,with one success-
ful feed in the control arm and one in the 0.2 mg/kg PQ arm. Two previ-
ous studies that determined transmission after DHAP found that 36%
(29/80) of symptomatic children (Rigby and Stasinopoulos, 2004) and
23% (3/13) of individuals with patent gametocytemia prior to treatment
(Dicko et al., 2016) infected at least one mosquito on day 7 after treat-
ment. Because of the limited number of infectious individuals in the
DHAP arm, our ﬁndings do not allow conclusive statements on the
transmission-blocking potential of PQ in this population. Other studies
that assessed infectivity after PQ maximized the discriminative power
of the feeding assays by purposefully selecting high-density gametocyte
carriers, likely to be infectious before treatment (Dicko et al., 2016;
Goncalves et al., 2016). We complement these ﬁndings with experi-
ments in a population that ismuch less likely to be infectious but consid-
erably more representative of the average malaria-infected population
(Slater et al., 2015; Imwong et al., 2016). We performed feeding experi-
ments on day 7 only. Two recent studies determined infectivity before
and at different time-points after treatment (Dicko et al., 2016;
Goncalves et al., 2016), thereby providing a valuable quality control of
the sensitivity of feeding experiments, which may vary considerably be-
tween settings and mosquito sources (Smith et al., 2000). Because we
onlymeasuredmalaria transmission seven days post treatment, we can-
not rule out a suboptimal sensitivity of our feeding assays and should
therefore be cautious when interpreting the results. Our data suggest
low infectivity of this population and that malaria transmission was
not fully prevented in the DHAP arm and the arm with the lowest PQ
dose (0.20 mg/kg).
A clinical trial on P. vivax treatment that was conducted after the ini-
tiation of the current study indicated that PQ efﬁcacy in clearing P. vivax
hypnozoites is inﬂuenced by genetic polymorphisms affecting PQ me-
tabolism by cytochrome P450 2D6 (CYP2D6) (Bennett et al., 2013).
The relevance of CYP2D6 variants for gametocyte clearance remains to
be established; we did not perform genotyping for CYP2D6 which re-
quires larger sample volumes (Dicko et al., 2016) and therefore cannot
determine its impact on gametocyte clearance or malaria transmission
after PQ.
In our study population, PQ was well tolerated with no statistically
signiﬁcant or clinically relevant hemolysis. Treatment-associated hemo-
lysis has been previously observed following a single dose PQ at 0.75
mg/kg (Eziefula et al., 2014a; Shekalaghe et al., 2010) and 0.4 mg/kg
(Eziefula et al., 2014a) and has been associated with G6PD deﬁciency.
In our trial, hemoglobin changes were observed in all trial arms with
the greatest difference from baseline,−7.5 g/dl observed on day 7 in
a female in the DHAP arm. However, she recovered completely without
clinical symptoms due to anemia. This pattern of marked drop in hemo-
globin followed by full recovery is commonly observed also in patients
with acute uncomplicated falciparum malaria (Ekvall et al., 2001)
and the current study does not show amarked effect of PQ on hemoglo-
bin concentrations post-treatment. It is important to acknowledge
that this trial was not designed to look at safety and included only
G6PD normal individuals with relatively high hemoglobin concentra-
tions (≥8 g/dl). If PQ is considered for inclusion in malaria control
programs, safety studies are needed with PQ at doses within the thera-
peutic range in G6PD deﬁcient individuals.
In conclusion, we report that a single course of PQ when given to-
gether with DHAP rapidly and signiﬁcantly reduces gametocytemia.
We observed very low levels of post-treatment infectivity to mosqui-
toes, which did not allow a robust comparison between treatment
arms. The low level of infection raises questions about the added value
of PQ in preventing transmission tomosquitoes 7 days post- treatment.
Future studies should address the safety of PQ in G6PD-deﬁcient
individuals.
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